Price
No data yet.
Social Signal Score
Revenue
$42.21M+28.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Aaron D. Berg
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 80
- Beta
- 0.77
- Country
- IE
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -1.88
Financials
Revenue
$42.21M+29.0%Net Income
$-7.65MEBITDA
$-11.33MFree Cash Flow
$40.26MEPS (diluted)
$-0.40Shares Outstanding (diluted)
20.82M+99.1%Operating Expenses
$26.96MCash & Debt
$314.65MReturn of Capital
$59.0KRevenue by Segment (annual)
$213.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $213.65M | $-38.80M | $-1.80 |
| 2024 | $228.61M | $-82.18M | $-4.00 |
| 2023 | $306.91M | $-59.11M | $-3.00 |
| 2022 | $369.19M | $-105.80M | $-5.20 |
| 2021 | $583.19M | $7.73M | $0.39 |
| 2020 | $614.06M | $-18.00M | $-0.94 |
| 2019 | $429.75M | $-22.64M | $-1.32 |
| 2018 | $229.21M | $-116.44M | $-7.80 |
| 2017 | $181.10M | $-67.86M | $-5.00 |
| 2016 | $130.08M | $-86.35M | $-8.20 |
| 2015 | $81.76M | $-115.20M | $-16.60 |
| 2014 | $54.20M | $-56.36M | $-6.40 |
| 2013 | $26.35M | $-166.23M | $-20.60 |
| 2012 | $0.00 | $-179.18M | $-24.80 |
Valuation
AMRNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsglobenewswire.com·6h ago·Negative
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28t h - 31st, in Munich, Germany.
View source ↗
Earnings
Wed, Nov 4(in 2 months)
Consensus estimate $-0.10 per share
Typical surprise -87.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$-0.02 vs $-0.01miss
- Wed, Apr 29$-0.09 vs $0.01miss
- Wed, Feb 25$0.01 vs $0.07miss
- Wed, Oct 29$0.01 vs $0.08miss
- Wed, Jul 30$-0.03 vs $-0.66beat
- Wed, May 7$-0.04 vs $-1.12beat
Estimates and results for AMRN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMRN officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.